PCSK9 inhibitors and diabetes risk: A question worth asking?

European Heart Journal

Volumn 37, Issue 39, 2016, Pages 2990-2992

  Sattar, Naveed ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALIROCUMAB; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9 INHIBITOR; SERINE PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

DIABETES MELLITUS; DRUG SAFETY; EDITORIAL; HUMAN; LIFESTYLE MODIFICATION; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 3 CLINICAL TRIAL (TOPIC); PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR;

ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PROPROTEIN CONVERTASE 9;

EID: 84994253432     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw346     Document Type: Editorial

References (13)

1. https://www.nice.org.uk/Guidance/CG181
2. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA;GAUSS-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance:The GAUSS-3 randomized clinical trial. JAMA 2016;315:1580-1590
3. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes:A collaborative meta-Analysis of randomised statin trials. Lancet 2010;375:735-742
4. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight:Evidence from genetic analysis and randomised trials. Lancet 2015;385:351-361
5. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:A metaanalysis. JAMA 2011;305:2556-2564
6. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, CorráU, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Løchen ML, Löllgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM;Authors/Task Force Members. 2016 European Guidelines on cardiovascular disease prevention in clinical practice:The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts):Developed with the special contribution of the European Association for Cardiovascular Prevention &Rehabilitation (EACPR). Eur Heart J 2016;37:2315-2381
7. Sattar N, Taskinen MR. Statins are diabetogenic-myth or reality? Atheroscler Suppl 2012;13:1-10
8. Besseling J, Kastelein JJ, Defesche JC, Hutten BA, Hovingh GK. Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. JAMA 2015;313:1029-1036
9. Colhoun HM, Ginsberg HN, Robinson JG, Leiter LA, Müller-Wieland D, Henry RR, Cariou B, Baccara-Dinet MT, Pordy R, Merlet L, Eckel RH. No effect of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY Phase 3 studies. Eur Heart J 2016;37:2981-2989
10. Bonnefond A, Yengo L, Le May C, Fumeron F, Marre M, Balkau B, Charpentier G, Franc S, Froguel P, Cariou B. The loss-of-function PCSK9 p.R46L genetic variant does not alter glucose homeostasis. Diabetologia 2015;58:2051-2055
11. Saveedra YG, Dufour R, Baass A. Familial hypercholesterolemia:PCSK9 InsLEU genetic variant and prediabetes/diabetes risk. J Clin Lipidol 2015;9:786-793.e1
12. http://www.nice.org.uk/guidance/indevelopment/gid-Tag512
13. http://www.nice.org.uk/guidance/indevelopment/gid-Tag498